BRAF leaders held more than 130 meetings with more than 300 people in an effort to understand how the foundation is perceived in the region and how it can serve nonprofits, philanthropists and the community as a whole, according to today’s announcement.

Source: https://www.businessreport.com/business/braf-releases-framework-for-promoting-thriving-and-resilient-future

The initial arm of the Phase 1 portion of the study will evaluate CFT1946 as a single agent in patients with BRAF V600 mutant solid tumors.

Source: https://forextv.com/top-news/c4-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-evaluating-cft1946-an-orally-bioavailable-bidac-degrader-in-braf-v600-mutant-solid-tumors/